Evidence map›Paper›PMID 27453816›Full record

ArticleLeukemia research reports2016

A case of SRSF2 mutation in chronic lymphocytic leukemia.

Eduardo Garza, Giovanni Del Poeta, Carmen Martínez-Losada, Gianfranco Catalano, Loredana Borgia, Maria Liliana Piredda, Emiliano Fabiani, Valter Gattei, Francesco Lo-Coco, Nélida I Noguera

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Eduardo GarzaLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Department of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy; Laboratorios Dr. Moreira, Monterrey, Mexico.
Giovanni Del PoetaDepartment of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
Carmen Martínez-LosadaLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Alfonso Martin Escudero Foundation, Madrid, Spain; Department of Hematology, IMIBIC, Hospital Universitario Reina Sofía, Universidad de Córdoba, Spain.
Gianfranco CatalanoDepartment of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
Loredana BorgiaLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Department of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
Maria Liliana PireddaLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Department of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
Emiliano FabianiDepartment of Hematology, Universita'Cattolica S. Cuore, Rome, Italy.
Valter GatteiClinical & Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Francesco Lo-CocoLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Department of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
Nélida I NogueraLaboratory of Neuro-Oncoematology, Santa Lucia Foundation, Rome, Italy; Department of Biomedicina e Prevenzione, "Tor Vergata" University, Rome, Italy.
University of Rome Tor Vergata · ITFondazione Santa Lucia · ITCentro di Riferimento Oncologico · ITInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by extremely variable clinical course indicating substantial differences in the biology of the disease. Molecular characterization provides new insights useful for treatment decision making. We report on a patient diagnosed with CLL, whose disease was characterized by episodes of rapid progression and disease stabilization, and in which a SRSF2 gene mutation was identified in the absence of other commonly known mutations of CLL. To the best of our knowledge this is the first case of SRSF2 gene mutation ever reported in CLL.

Indexed as

Chronic lymphocytic leukemiaClinical aspectGenetic analysisSRSF2

Identifiers

PMID27453816
PMCPMC4941199
OpenAlexW2469461820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.